Atara Biotherapeutics, Inc. ATRA
Set alert
8.48 USD +0.47 +5.87%
At close · Nov 2
8.48 0.00 0.00%
After hours · Nov 2, 4:33 PM ET
8.02 Day range 8.59
3.92 52-week range 19.15
- YTD
- -53.12%
- 1 year
- -42.90%
- Open
- 8.05
- Prev close
- 8.01
- Mkt cap
- 85.12M
- Vol
- 32.05K
- Avg vol
- 41.51K
- EPS
- -1.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.02
- High
- 8.59
- Forward P/E
- -1.52
- Beta
- 0.49
- Short ratio
- 7.11
- Inst. own
- 50.82%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.80
- 200-d avg
- 11.70
- 1y target
- 16.33
3M chart
Signals (25)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
Newest 20 of 25.
Financial health
Altman Z-Score
-135.86 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E 6.9×
FY 2016 5y median -1.2× FY 2025
P/S 1.9×
FY 2016 5y median 5.3× FY 2025
P/B -5.9×
FY 2016 5y median -0.5× FY 2025
P/FCF -4.5×
FY 2016 5y median -1.4× FY 2025
EV/EBITDA 7.0×
FY 2016 5y median -1.4× FY 2025
EV/Sales 2.2×
FY 2016 5y median 4.9× FY 2025
FCF Yield -22.4%
FY 2016 5y median -69.2% FY 2025
Profitability
Gross Margin 82.4%
FY 2016 5y median -3.7% FY 2025
Operating Margin 29.7%
FY 2016 5y median -441.2% FY 2025
Net Margin 27.1%
FY 2016 5y median -359.1% FY 2025
ROE -84.9%
FY 2016 5y median -84.9% FY 2025
ROIC 222.7%
FY 2016 5y median -90.2% FY 2025
ROA 161.5%
FY 2016 5y median -72.7% FY 2025
Growth (YoY)
Revenue -6.3%
FY 2016 FY 2025
Operating Income 143.0%
FY 2016 FY 2025
EPS (diluted) 122.5%
FY 2016 FY 2025
Free Cash Flow 26.1%
FY 2016 FY 2025
Financial Health
Current Ratio 0.8×
FY 2016 5y median 0.8× FY 2025
Quick Ratio 0.8×
FY 2016 5y median 0.8× FY 2025
Debt / Equity -1.4×
FY 2016 5y median -0.5× FY 2025
Net Debt / EBITDA 1.1×
FY 2016 5y median 0.1× FY 2025
Interest Coverage 9.5×
FY 2016 5y median -18.1× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
